Four peptides decrease the number of human pancreatic adenocarcinoma cells

European Journal of Clinical Investigation

Volumn 33, Issue 11, 2003, Pages 998-1005

  Vesely, B A ^a,b   McAfee, Q ^a,b   Gower Jr , W R ^a,b   Vesely, D L ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Cancer; Cyclic GMP; DNA synthesis; Peptide hormones

Indexed keywords

ATRIAL NATRIURETIC FACTOR ALPHA; BROXURIDINE; CYCLIC GMP DEPENDENT PROTEIN KINASE; PEPTIDE HORMONE; PROATRIAL NATRIURETIC FACTOR[1-30]; PROATRIAL NATRIURETIC FACTOR[31-67]; PROATRIAL NATRIURETIC FACTOR[79-98]; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL COUNT; CELL PROLIFERATION; DNA SYNTHESIS INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL;

ADENOCARCINOMA; APOPTOSIS; ATRIAL NATRIURETIC FACTOR; CELL DIVISION; CYCLIC GMP; DINOPROSTONE; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PANCREATIC NEOPLASMS; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; TUMOR CELLS, CULTURED;

EID: 0242469264     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2003.01262.x     Document Type: Article

References (46)

1. Brenner BM, Ballermann BJ, Gunning ME, Zeidel ML. Diverse biological actions of atrial natriuretic peptide. Physiol Rev. 1990;70:665-99.
2. Vesely DL. Atrial natriuretic peptide prohormone gene expression: Hormones and diseases that upregulate its expression. IUBMB Life 2002;53:153-9.
3. Vesely DL, Norris JS, Walters JM, Jespersen RR, Baeyens DA. Atrial natriuretic prohormone peptides 1-30, 31-67 and 79-98 vasodilate the aorta. Biochem Biophys Res Commun 1987;148:1540-8.
4. 2-terminus are natriuretic and/or kaliuretic. Am J Physiol 1990;258:F1401-F1408.
5. 2. J Clin Invest 1992;89:1411-7.
6. Benjamin BA, Peterson TV. Effects of proANF (31-67) on sodium excretion in conscious monkeys. Am J Physiol 1995;269:R1351-R1355.
7. + reabsorption by ANP 31-67. Clin Exp Pharmacol Physiol 1995;22:121-4.
8. Villarreal D, Reams GP, Taraben A, Freeman RH. Hemodynamic and renal effects of proANF 31-67 in hypertensive rats. Proc Soc Exp Biol Med 1999;221:166-70.
9. Dietz JR, Scott DY, Landon CS, Nazian SJ. Evidence supporting a physiological role for proANP (1-30) in the regulation of renal excretion. Am J Physiol, 2001;280:R1510-R1517.
10. Vesely DL, Douglass MA, Dietz JR, Giordano AT, McCormick MT, Rodriguez-Paz G et al. Negative feedback of atrial natriuretic peptides. J Clin Endocrinol Metab 1994;78:1128-34.
11. Vesely DL, Douglass MA, Dietz JR, Gower WR Jr, McCormick MT, Rodriguez-Paz G et al. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis and/or kaliuresis in humans. Circulation 1994;90:1129-40.
12. Vesely DL, Dietz JR, Parks JR, Baig M, McCormick MT, Cintron G et al. Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure. Circulation 1998;98:323-9.
13. Vesely DL. Atrial Natriuretic Hormones. Englewood Cliffs, NJ: Prentice Hall; 1992. pp. 1-256.
14. Vesely DL. Natriuretic peptides and acute renal failure. Am J Physiol 2003;285:F167-F177.
15. Winters CJ, Sallman AL, Baker BJ, Meadows J, Rico DM, Vesely DL. The N-terminus and a 4000 molecular weight peptide from the mid portion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. Circulation 1989;80:438-49.
16. Vesely DL, Norsk P, Winters CJ, Rico DM, Sallman AL, Epstein M. Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans. Proc. Soc Exp Biol Med 1989;192:230-5.
17. Hunter EFM, Kelly PA, Prowse C, Woods FJ, Lowry PJ. Analysis of peptides derived from pro atrial natriuretic peptide that circulate in man and increase in heart disease. Scan J Clin Lab Invest 1998;58:205-16.
18. Franz M, Woloszczuk W, Horl WH. N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment. Kidney Int, 2000;58:374-8.
19. De Palo EF, Woloszczuk W, Meneghetti M, DePalo CB, Nielsen HB, Secher NH. Circulating immunoreactive proANP (1-30) and proANP (31-67) in sedentary subjects and athletes. Clin Chem, 2000;46:843-7.
20. Franz M, Woloszczuk W, Horl WH. Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney diseases. Kidney Int, 2001;59:1928-34.
21. Toshimori H, Toshimori K, Oura C, Matsuo H. Immunohistochemical study of atrial natriuretic polypeptides in the embryonic fetal and neonatal rat heart. Cell Tissue Res 1987;248:627-33.
22. Abell TJ, Richards AM, Ikram H, Espiner EA, Yandle T. Atrial natriuretic factor inhibits proliferation of vascular smooth muscle cells stimulated by platelet derived growth factor. Biochem Biophys Res Commun 1989;160:1392-6.
23. Itoh H, Pratt RE, Dazu VJ. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest 1990;86:1690-7.
24. Itoh H, Pratt TE, Ohno M, Dazu VJ. Atrial natriuretic polypeptide as a novel antigrowth factor of endothelial cells. Hypertension 1992;19:758-61.
25. Johnson A, Lermioglu F, Garg UC, Morgan-Boyd R, Hassid A. A novel biological effect of atrial natriuretic hormone: inhibition of mesangial cell mitogenesis. Biochem Biophys Res Commun 1988;152:893-7.
26. Appel RG. Growth inhibitory activity of atrial natriuretic factor in rat glomerular mesangial cells. FEBS Lett 1988;238:135-8.
27. Appel RG. Mechanism of atrial natriuretic factor-induced inhibition of rat mesangial cell mitogenesis. Am J Physiol 1990;259:E312-E318.
28. Appel RG. Growth-regulatory properties of atrial natriuretic factor. Am J Physiol 1992;262:F911-F918.
29. Haneda M, Kikkawa R, Koya D, Sakamoto K, Nakanishi S, Matsuda Y et al. Biological receptors mediate anti-proliferative action of atrial natriuretic peptide in cultured mesangial cells. Biochem Biophys Res Commun 1993;192:642-8.
30. Pedram A, Razandi M, Hu TM, Levin ER. Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J Biol Chem 1997;272:17097-103.
31. Yu SM, Hung LM, Lin CC. cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibition the activation of epidermal growth factor signaling pathway. Circulation 1997;95:1269-77.
32. Calderone A, Thaik CM, Takahashi N, Chang DLF, Colucci WS. Nitric oxide, atrial natriuretic peptide and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 1998;101:812-8.
33. Pitchumoni CS. In: Stein JH, editor. Internal Medicine. St Louis: Mosby; 1998. pp. 2233-47.
34. Wolff RA, Abbruzzese JL, Evans DB. In: Holland JF, Frei E III, editors. Cancer Medicine. London: BC Decker Inc; 2000. pp. 1436-64.
35. Gower WR Jr, Risch RM, Godellas CV, Fabri PJ. HPAC, a new human glucocorticoid-sensitive pancreatic ductal adenocarcinoma cell line. In Vitro Cell Dev Biol 1994;30A:151-61.
36. Gratzner HG. Monoclonal antibody to 5-bromo-ad 5-lododeoxyuridine. A new reagent for detection of DNA replication. Science 1982;218:474-5.
37. Yu CCW, Woods AL, Levison DA. The assessment of cellular proliferation by immunohistochemistry: a review of currently available methods and their applications. Histochemical J. 1992;24:121-31.
38. Morstyn G, Pyke K, Gardner J, Ashcroft R, deFazio A, Bhathal P. Immunohistochemical identification of proliferatory cells in organ culture using bromodeoxyuridine and a monoclonal antibody. J Histochem Cytochem 1986;34:697-701.
39. Qin Y, Williams G. Comparison of the classical autoradiographic and immunohistochemical methods with BrdU for measuring proliferation parameters in colon cancer. Anticancer Res 1993;13:731-6.
40. Waldman SA, Rapoport RM, Murad F. Atrial natriuretic factor selectively activates membranous guanylate cyclase and elevates cyclic GMP in rat tissues. J Biol Chem 1984;259:14332-4.
41. +-ATPase of the atrial natriuretic peptides. Endocrinology 1995;136:2033-9.
42. Vesely DL. Signal transduction: Activation of the guanylate cyclase-cyclic guanosine-3′5′ monophosphate system by hormones and free radicals. Am J Med Sci 1997;314:311-23.
43. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Ann Rev Cell Dev Biol 1999;15:269-90.
44. Rashed HM, Sun H, Patel TB. Atrial natriuretic peptide inhibits growth of hepatoblastoma (HEP G2) cells by means of activation of clearance receptors. Hepatology 1993;17:677-84.
45. Liu CD, Rongione AJ, Garvey L, Balasuabramaniam A, McFadden DW. Adjuvant hormonal treatment with peptide YY or its analog decreases human pancreatic carcinoma growth. Am J Surg 1996;171:192-6.
46. Wu CF, Bishopric NH, Pratt RE. Atrial natriuretic peptide induces apoptosis in neonatal rat cardiac myocytes. J Biol Chem 1997;272:14860-6.